The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use-Reference-Cited by-同舟云学术

The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Published:2013-04-24 Issue:5 Volume:18 Page:625-633
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Péan Elias¹,Flores Beatriz²,Hudson Ian²,Sjöberg Jan³,Dunder Kristina³,Salmonson Tomas³,Gisselbrecht Christian⁴,Laane Edward⁵,Pignatti Francesco¹

Affiliation:

1. European Medicines Agency, London, United Kingdom;

2. Medicines and Healthcare Products Regulatory Agency, London, United Kingdom;

3. Läkemedelsverket, Medical Products Agency, Uppsala, Sweden;

4. Hôpital Saint Louis, Paris, France;

5. North Estonia Regional Hospital, Tallinn, Estonia

Abstract

Learning Objectives Describe the efficacy profile of pixantrone in patients with relapsed or refractory NHL. Identify the most frequent toxicities associated with pixantrone treatment.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2013-0020

Reference10 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

3. Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: Aza-anthracenediones;Hazlehurst;Cancer Lett,1995

4. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone;Cavalletti;Invest New Drugs,2007

5. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly;Dawson;Eur J Cancer,2000

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Repurposing of Selected Antibiotics: An Emerging Approach in Cancer Drug Discovery;ACS Omega;2024-06-13

2. Encapsulation of pixantrone into PEGylated liposomes enhances its antineoplastic efficacy and reduces thymus toxicity;Journal of Drug Delivery Science and Technology;2023-09

3. Anthracyclines React with Apurinic/Apyrimidinic Sites in DNA;ACS Chemical Biology;2023-05-18

4. An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells;Cancer Chemotherapy and Pharmacology;2022-04-23

5. Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance);The Oncologist;2022-04-21